Xencor (XNCR) Share-based Compensation (2013 - 2026)
Xencor (XNCR) reported Share-based Compensation of $9.6 million for Q1 2026, down 21.71% year-over-year from $12.2 million in Q1 2025, and down 6.13% quarter-over-quarter from $10.2 million in Q4 2025.
Xencor (XNCR) Share-based Compensation (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Share-based Compensation data on file, last reported at $9.6 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $9.6 million, down 21.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.6 million (down 24.96% YoY), and the FY2025 annual result was $43.2 million, down 18.87% from the prior year.
- Share-based Compensation fell to $9.6 million in Q1 2026 per XNCR's latest filing, from $10.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $17.2 million in Q2 2024 and troughed at $9.6 million in Q1 2026.
- A 5-year average of $12.3 million and a median of $12.3 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 42.68% in 2022, then plunged 37.54% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $12.7 million in 2022, then increased by 15.32% to $14.7 million in 2023, then retreated by 16.09% to $12.3 million in 2024, then dropped by 17.41% to $10.2 million in 2025, then decreased by 6.13% to $9.6 million in 2026.
- Business Quant data shows XNCR's Share-based Compensation at $9.6 million in Q1 2026, $10.2 million in Q4 2025, and $10.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 9.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.56 Mn |
| Mar 31, 2026 | 9.56 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Dec 31, 2023 | 14.70 Mn |
| Dec 31, 2023 | 14.70 Mn |